You are here

Amgen

Amgen Battles IRS Over Billions in "Wholly Unwarranted" Tax Penalties

BioSpace

Wed, 04/27/22 - 10:47 pm

A bad day for Molecular Partners

EP Vantage

Wed, 04/27/22 - 10:45 am

Molecular Partners

Thought CETP inhibition was dead? Think again

EP Vantage

Sat, 04/23/22 - 04:17 pm

CETP inhibitors

Amgen parts ways with part of Ventura County headquarters campus: report

Fierce Pharma

Thu, 04/14/22 - 10:44 am

Novartis Highlights Early Data from Potential Lumakras Competitor at AACR

BioSpace

Tue, 04/12/22 - 10:49 am

clinical trials

AACR: 2 years in, Amgen fortifies Lumakras lung cancer data fortress for upcoming Mirati, Novartis KRAS battle

Fierce Pharma

Sun, 04/10/22 - 07:46 pm

Mirati Therapeutics

ACC 2022 – Astra’s cholesterol lowerer surprise comes just a little late

EP Vantage

Tue, 04/5/22 - 10:59 am

Ionis Pharmaceuticals

As Eli Lilly grows beyond Research Triangle Park, biopharmas big and small are tapping North Carolina's 'limitless' potential

Fierce Pharma

Tue, 03/8/22 - 10:22 am

Jaguar Gene Therapy

Plexium nabs $102M for protein degradation work weeks after $500M Amgen tie-up

Fierce Biotech

Wed, 02/23/22 - 10:34 am

protein degradation

venture capital

Innovent's phase 3 hits tee it up to challenge Amgen and Sanofi for Chinese PCSK9 market

Fierce Biotech

Thu, 02/17/22 - 10:56 am

Innovent Biologics

clinical trials

Amgen Snags Another Approval for This Promising Cancer Drug

Motley Fool

Wed, 02/16/22 - 10:48 am

non-small cell lung cancer

advanced non-small cell lung cancer

Amgen hold-up gives Mirati a vital lifeline

EP Vantage

Thu, 02/10/22 - 10:12 am

Mirati Therapeutics

clinical trials

Amgen talks long-term growth, but doubts remain for analysts, investors

Fierce Pharma

Tue, 02/8/22 - 11:54 pm

Amgen, Plexium Collaborate To Identify Novel Targeted Protein Degradation Therapies

NASDAQ

Thu, 02/3/22 - 11:34 am

targeted protein degradation

Novartis, Amgen settle their dueling lawsuits over migraine drug Aimovig

Fierce Pharma

Tue, 02/1/22 - 11:28 pm

Amgen Wins Another Key Approval for This Potential Blockbuster Cancer Drug

Motley Fool

Thu, 01/27/22 - 11:36 pm

non-small cell lung cancer

JPM 2022: Novartis rewrites the drug launch playbook with Leqvio, and it doesn't plan to stop there, exec says

Fierce Pharma

Thu, 01/13/22 - 11:06 am

7 drugs likely to hit $1B in annual revenue in the next 5 years

Beckers Hospital Review

Thu, 01/13/22 - 07:31 am

Mirati Therapeutics

JPM22, Day 3: In short order, Perrigo part of a new landscape; Legend, J&J prep for cilta-cel launch

Fierce Pharma

Wed, 01/12/22 - 11:22 pm

Pages